Clinical Trials
63 trialsTAURUS
European Myeloma Network B.V.
Romidepsin and Lenalidomide in Treating Patients With Previously Untreated Peripheral T-Cell Lymphoma
Northwestern University
A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Transplant Ineligible
Hellenic Society of Hematology
Selinexor Treatment for Multiple Myeloma Patients Who Are Refractory to Lenalidomide-containing Therapy.
Oncotherapeutics
ZR2 Followed by Immunochemotherapy in Elderly Patients With Newly-diagnosed DLBCL
Zhejiang Cancer Hospital
CURATE.AI Optimized Modulation for Multiple Myeloma
National University Hospital, Singapore
LENDER
Kosin University Gospel Hospital
VRD as Induction Followed by VR Maintenance in Patients With Newly Diagnosed High Risk Multiple Myeloma
Sun Yat-sen University
A Clinical Study of Injectable IMM0306 in Combination With Lenalidomide
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
The Efficacy and Safety of ZR2 Versus R-miniCHOP in the Treatment of Unfit or Frail de Novo Diffuse Large B-cell Lymphoma Patients Aged Older Than or Equal to 70 Years
Ruijin Hospital
Lenalidomide, Adriamycin, Dexamethasone (RAD) Versus Lenalidomide, Bortezomib, Dexamethasone (VRD) for Induction in Newly Diagnosed Multiple Myeloma Followed by Response-adapted Consolidation and Lenalidomide Maintenance
Wuerzburg University Hospital
The Efficacy and Safety of Colchicine Combined With Conventional Therapy in Multiple Myeloma Patients
Affiliated Hospital of Nantong University
GZL Sequential CD19/CD22 CAR-T in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
The First Affiliated Hospital of Soochow University
Selinexor in Combination With Immunomodulator ļ¼Thalidomide/Pomalidomide/Lenalidomideļ¼in RRMM
Shanghai Changzheng Hospital
Relyage
Centre Hospitalier Universitaire, Amiens
Lenalidomide, Dexamethasone, and Elotuzumab With or Without Cyclophosphamide in Treating Patients With Relapsed Primary Amyloidosis
Barbara Ann Karmanos Cancer Institute
Mitoxantrone Hydrochloride Liposome Combined With Rituximab and Lenalidomide (M+R2) in Patients With Relapsed and Refractory Diffuse Large B-Cell Lymphoma
Huazhong University of Science and Technology
FIL_KLIMT
Fondazione Italiana Linfomi - ETS
KMM1910
Samsung Medical Center
A Phase 2 Study of Isatuximab in Combination With Bortezomib, Cyclophosphamide and Dexamethasone Followed by Isatuximab and Lenalidomide Maintenance in Newly Diagnosed Patients With Multiple Myeloma and Severe Renal Impairment
Hellenic Society of Hematology
Study of Azacytidine Combined With Lenalidomide As Maintenance Therapy Based on MRD Monitoring in AML
Zhongda Hospital
ZR2-CHOP
The First Affiliated Hospital with Nanjing Medical University
Penpulimab Plus R2-GemOx Regimen in Relapsed or Refractory DLBCL
The First Affiliated Hospital with Nanjing Medical University
DNA Vaccination Against Neuroblastoma
Belarusian Research Center for Pediatric Oncology, Hematology and Immunology
GEM-CLARIDEX
PETHEMA Foundation
DLCL002 Protocol for Patients With High Risk Aggressive B-cell Lymphoma
Institute of Hematology & Blood Diseases Hospital, China
PD1 Antibody and Lenalidomide as a Treatment for EBV-HLH or CAEBV
Beijing Friendship Hospital
Dose Escalation and Expansion Study of CM313 in Subjects With Relapsed or Refractory Multiple Myeloma and Lymphoma
Keymed Biosciences Co.Ltd
A Study of OLR in First-line Treatment of Mantle Cell Lymphoma
Tianjin Medical University Cancer Institute and Hospital
Study of BiRd Regimen Combined With BCMA CAR T-cell Therapy in Newly Diagnosed Multiple Myeloma (MM) Patients
The First Affiliated Hospital of Soochow University
Orelabrutinib in Combination With R2 Regimen for R/R CD20+ B-cell Lymphoma
Puyang Oilfield General Hospital
FiTNEss
University of Leeds
Study Evaluating the Safety and Efficacy of iR2 in Untreated and Unfit Elderly Patients With DLBCL
Ruijin Hospital
Biomarker Guided Treatment in DLBCL
Ruijin Hospital
LCMALT
National Taiwan University Hospital
Lenalidomide Plus R-CHOP for CNS Relapse Prophylaxis in Diffuse Large B-cell Lymphoma
Nanfang Hospital, Southern Medical University
IFM2018-01
University Hospital, Toulouse
Lenalidomide in Combination With R-GemOx in First-line Treatment of Elderly Diffuse Large B Cell Lymphoma
The First Affiliated Hospital with Nanjing Medical University
The Safety and Tolerability of PD-L1 Monoclonal Antibody Plus Lenalidomide in The Treatment of Colorectal Cancer
Henan Cancer Hospital
PD-1 Antibody, Chidamide, Lenalidomide and Gemcitabine for Peripheral T-cell Lymphoma
Zhengzhou University
Chidamide Combination With Lenalidomide in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma
Sun Yat-sen University
NK Cells in Cord Blood Transplantation
M.D. Anderson Cancer Center
MUKeleven
University of Leeds
Intravitreal Methotrexate and R2(Rituximab & Lenalidomide) Regimen in Newly-diagnosed Primary Vitreoretinal Lymphoma
Peking Union Medical College Hospital
LEGEND
Royal Marsden NHS Foundation Trust
PD-1 Antibody, Chidamide, Lenalidomide and Etoposide for Relapsed or Refractory NK/T Cell Lymphoma
Zhengzhou University
R2 in the Treatment of Follicular Lymphoma
Ruijin Hospital
Phase 2 Trial of Chidamide-Lenalidomide-Dexamethasone(CRD) Regimen in R/R MM
Shanghai Zhongshan Hospital
Myeloma XI
University of Leeds
MCL0208
Fondazione Italiana Linfomi - ETS